Drug profile · INN
benralizumab
FASENRA PEN
benralizumab (FASENRA PEN) is a interleukin-5 receptor subunit alpha inhibitor. Associated with AstraZeneca. Route of administration: injection. Current US regulatory status: approved.
Drug details — benralizumab
- US status
- approved
- Class
- Respiratory system (R03)
- Route
- INJECTION
- Patents
- 15
- Programs
- 11
- Data quality
- 0.84
Quick answer
benralizumab (FASENRA PEN) is a interleukin-5 receptor subunit alpha inhibitor. Associated with AstraZeneca. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-5 receptor subunit alpha inhibitor
Primary target: Interleukin-5 receptor subunit alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
-
US 11052029
Cation compatible metal oxides and oral care compositions containing the metal oxides
granted -
US 11000711
Compositions for forming films having a desired degree of obscuration and methods of making and using the same
granted -
US 10660856
Porous silica gel as a carrier for liquid technologies
granted -
US 10525290
Compositions for forming films having a desired degree of obscuration and methods of making and using the same
granted -
US 7964612
Therapeutic pyrazolyl thienopyridines
granted -
US 7820398
Immunosorbent blood tests for assessing paroxysmal cerebral discharges
granted -
US 7678918
Intermediates for imidazonaphthyridines
granted -
US 7615230
Method for decreasing sebum production
granted -
US 7335773
Intermediates for imidazonaphthyridines
granted -
US 6896876
High cleaning silica gel dental abrasive, dentifrices prepared therefrom, and a method for preparing the dental abrasive
expired -
US 6585960
Abrasive silica compositions and dentifrice compositions prepared therefrom
expired -
US 6440397
Abrasive silica compositions and dentifrice compositions prepared therefrom
expired -
US 6426201
&bgr;-glucan products and extraction processes from cereals
expired -
US 6294155
Abrasive silica compositions and dentifrice compositions prepared therefrom
expired -
US 6239110
Synthetic analogs of thrombospondin and therapeutic use thereof
expired
Frequently asked questions
What is benralizumab?
benralizumab (FASENRA PEN) is a interleukin-5 receptor subunit alpha inhibitor. Associated with AstraZeneca. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for benralizumab?
FASENRA PEN is a marketed brand name for benralizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of benralizumab?
benralizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.